Comprehensive primary prevention of cardiovascular disease in women

Suegene K. Lee | Jay Khambhati | Tina Varghese | Eric P. Stahl | Sonali Kumar | Pratik B. Sandesara | Nanette K. Wenger | Laurence S. Sperling

Division of Cardiology, Department of Medicine, Emory University School of Medicine, Georgia

Correspondence
Laurence Sperling, MD, 1365 Clifton Road NE, Building A, Suite 2200, Atlanta, GA 30322
Email: lsperli@emory.edu

Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of mortality in women. Historically, medical research has focused on male patients, and subsequently, there has been decreased awareness of the burden of ASCVD in females until recent years. The biological differences between sexes and differences in societal expectations defined by gender roles contribute to gender differences in ASCVD risk factors. With these differing risk profiles, risk assessment, risk stratification, and primary preventive measures of ASCVD are different in women and men. In this review article, clinicians will understand the risk factors unique to women, such as preeclampsia, gestational diabetes, and those that disproportionately affect them such as autoimmune disorders. With these conditions in mind, the approach to ASCVD risk assessment and stratification in women will be discussed. Furthermore, the literature behind the effects of primary preventive measures in women, including lifestyle modifications, aspirin, statins, and anticoagulation, will be reviewed. The aim of this review article was to ultimately improve ASCVD primary prevention by reducing gender disparities through education of physicians.

KEYWORDS
Cardiovascular Disease, Disparities, Prevention, Women

1 | INTRODUCTION

Although traditionally misconceived as a “man’s disease,” atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death among women. With an increase in awareness and appropriate therapies, ASCVD-associated deaths among both genders >65 years of age in the United States have declined. However, there has been an increase in the average annual rate of death from coronary heart disease (CHD) among young women aged 35 to 54 years, whereas there has been a decrease in the annual rate of death in men of the same age group. The gender differences in ASCVD risk profiles (Figure 1) are, therefore, important to understand to reduce this burden on women. These differences range from varying sex-chromosome–related gene expression to differing behaviors, lifestyles, environment, and expectations arising from sociocultural practices according to gender. Based on these differences, the American Heart Association (AHA) published guidelines for the prevention of cardiovascular (CV) disease in women in 2011. A high-level overview of these guidelines in conjunction with additional evidence on prevention of ASCVD that has emerged since 2011 will be discussed to provide a comprehensive approach to risk assessment and stratification of ASCVD in women, as well as a review of effective preventive measures.

2 | RISK FACTORS FOR CV DISEASE UNIQUE TO WOMEN

2.1 | Hypertensive disorders of pregnancy

Although gestational hypertension and preeclampsia resolve within 3 months postpartum, they are associated with residual vascular dysfunction and increased ASCVD risk in women, recognized as a major risk factor by the 2011 AHA guidelines. The placenta is hypoperfused, and inflammatory cytokines and antiangiogenic proteins are released in preeclampsia, leading to
2.14). However, only 3 of the 25 studies adjusted for diabetes, metabolic syndrome, and smoking, and most only adjusted for age. It is unclear if there is a common cause for preeclampsia and ASCVD. The use of unopposed estrogen did not affect CHD (HR: 0.91; 95% CI: 0.75-1.12), but increased the risk of stroke (HR: 1.39; 95% CI: 1.10-1.77) and total CV disease (HR: 1.12; 95% CI: 1.01-1.24). There was no difference in incidence of CHD events between the estrogen-progestin and placebo group in the HERS trial, despite a decrease in low-density lipoprotein (LDL) and an increase in high-density lipoprotein (HDL) in the experimental group. Based on these results, the current recommendation of the US Preventive Services Task Force is against the use of combined estrogen and progestin or estrogen alone for prevention of ASCVD in menopausal women.

2.4 | Menopause and menopausal hormone therapy

The American College of Cardiology (ACC)/AHA identifies postmenopausal status as a risk factor for ASCVD. However, an important confounding variable to this association is the increase in the traditional ASCVD risk factors in postmenopausal women. With observational studies in the late 1980s showing protective effects of estrogen on the heart and menopause's contribution to a higher risk of ASCVD, physicians began prescribing long-term estrogen therapy as primary prevention for CHD. Estrogen modulates the nitric oxide and vasodilation pathway after binding to estrogen receptor-α on endothelial cells, and thereby improves endothelial function. However, the results of the Women's Health Initiative (WHI) and the Heart and Estrogen/Progestin Replacement Study (HERS) shifted this paradigm. The combined estrogen-progestin therapy group of the WHI was at increased risk for total ASCVD, including CHD (hazard ratio [HR]: 1.29; 95% CI: 1.02-1.63), stroke (HR: 1.41; 95% CI: 1.07-1.85), and total CV disease (HR: 1.22; 95% CI: 1.09-1.36) over an average follow-up of 5.2 years. The use of unopposed estrogen did not affect CHD (HR: 0.91; 95% CI: 0.75-1.12), but increased the risk of stroke (HR: 1.39; 95% CI: 1.10-1.77) and total CV disease (HR: 1.12; 95% CI: 1.01-1.24). There was no difference in incidence of CHD events between the estrogen-progestin and placebo group in the HERS trial, despite a decrease in low-density lipoprotein (LDL) and an increase in high-density lipoprotein (HDL) in the experimental group. Based on these results, the current recommendation of the US Preventive Services Task Force is against the use of combined estrogen and progestin or estrogen alone for prevention of ASCVD in menopausal women.

3 | RISK FACTORS FOR CV DISEASE THAT DISPROPORTIONATELY AFFECT WOMEN

3.1 | Autoimmune disorders

Systemic autoimmune disorders occur predominantly in women, which predisposes them to chronic inflammation, endothelial dysfunction, and accelerated atherosclerosis. Women with systemic lupus erythematosus (SLE) between the ages of 35 and 44 years were found to be more likely to have an MI, compared to their age-matched counterparts.
matched counterparts in the Framingham cohort (RR: 52.43; 95% CI: 21.6-98.5).12

4 | GENDER DISPARITIES IN TRADITIONAL ASCVD RISK FACTORS

In both women and men, the traditional risk factors, including hypertension, dyslipidemia, diabetes mellitus, and smoking, are strongly associated with ASCVD risk. However, there are sex differences in prevalence and magnitude of associated ASCVD risk (Table 1). Obesity and sedentary behavior are more common in women.13 Weight gain during pregnancy may contribute to the sex difference in the prevalence of obesity, whereas barriers to physical activity (PA) are different in women than in men, in part because of traditional female gender roles such as caretaker responsibilities.14 Smoking is more prevalent in men (20.5%) than in women (15.9%), but the relative risk of CHD associated with smoking is 25% greater in women than in men, even after adjustment for other CV risk factors.15 The reason for this discrepancy is not known. Differences in nicotine metabolism and smoking behavior have been suggested as possible mechanisms.

Diabetic women are more likely to both develop and die from CVD than their male counterparts.16 In fact, impaired fasting glucose alone causes increased CHD risk in women to a similar extent as diabetes does, an association not observed in men.17 Despite this, diabetic women with CHD are less likely to be treated with aspirin and less likely to have their hyperlipidemia and hypertension optimized than similarly affected men.18 Women are also less likely to have their hypertension controlled compared to men (54% vs 58.7%, respectively; P < 0.02), especially with older age (53.4% vs 63.2% for ages 65–80 years; P < 0.005).19

5 | GENDER DISPARITIES IN NONTRADITIONAL ASCVD RISK FACTORS

5.1 | Depression
Depression is associated with increased mortality following MI and moderately increased risk for future major adverse cardiac events.20 In the large, international case–control study INTERHEART (The Effect of Potentially Modifiable Risk Factors Associated with Myocardial Infarction in 52 countries), psychosocial factors had significant gender differences: women had higher contributions from psychosocial risk factors (45.2% vs 28.8% in men).21 A study of 3237 patients found that depressive symptoms predicted the presence of coronary artery disease (CAD) in women ≤55 years old (OR: 1.07; 95% CI: 1.02-1.13) and increased risk of death in this group of women (adjusted HR: 1.07; 95% CI: 1.02-1.14).22

5.2 | Social determinants of health
Psychosocial stressors, such as perceived stress, life events, have been associated with increased ASCVD risk.23 Women are especially vulnerable, as they represent 60% of the world’s poor and 66% of illiterate adults,24 given the differential distribution of income in men vs women. The WISE (Women’s Ischemia Syndrome Evaluation) study showed that income was a significant predictor of CV death or MI, after adjusting for angiographic coronary disease, chest pain symptoms, and traditional risk factors.25

5.3 | Risk markers for atherosclerosis
The 2013 ACC/AHA guidelines recommend addressing novel markers to enhance risk classification in individuals at intermediate risk.25 Inflammatory markers, such as high-sensitivity C-reactive protein

<table>
<thead>
<tr>
<th>TABLE 1</th>
<th>Traditional ASCVD risk factors in women</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk Factor</td>
<td>Sex-Based Differences</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>Diabetic women are more likely to develop and die from CVD than their male counterparts.</td>
</tr>
<tr>
<td>Hypertension</td>
<td>Over the age of 60 years, hypertension is more prevalent in women than men.</td>
</tr>
<tr>
<td>Obesity, physical inactivity</td>
<td>In the United States, obesity is more common in women than in men (35.5% vs 33.8%).</td>
</tr>
<tr>
<td>Smoking</td>
<td>There is 25% greater relative risk of CHD with smoking in women than in men.</td>
</tr>
</tbody>
</table>

Abbreviations: ACC, American College of Cardiology; ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure; CHD, coronary heart disease; CVD, cardiovascular disease; DM, diabetes mellitus; JNC8, 8th Joint National Committee; PAR, population-attributable risk.
hsCRP, are thought to be subclinical markers associated with increased CV risk independent of a woman's lipid profile. hsCRP is the most extensively examined of the novel markers addressing CV risk. In the JUPITER (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) trial, asymptomatic women ≥60 years old and men ≥50 years old with elevated hsCRP (≥2 mg/L), low LDL levels (<130 mg/dL), and triglyceride levels <500 mg/dL were randomized to receive statin or placebo therapy. In those treated with statin therapy, incident ASCVD was reduced by 44% and all-cause mortality by 20%.

The coronary artery calcium (CAC) score was developed as a non-invasive marker for vascular disease. Calcification of the coronary arteries is measured in Hounsfield units in gated computed tomography imaging, and is converted to an Agatston score (area x density). In the MESA (Multi-Ethnic Study of Atherosclerosis) study, the relative risk for developing CAC in those deemed intermediate to high risk (>10%) by the Framingham Risk Score, compared to low risk (<10%) was 2.41 (95% CI: 1.57-3.72) in women and 1.62 (95% CI: 1.16-2.27) in men (P value for interaction 0.07). Although currently not endorsed for routine screening by the guidelines, a CAC score can be a useful method to reclassify risk assessment when a patient's risk based on ASCVD pooled cohort equation is unclear or intermediate.

### 6 | RISK ASSESSMENT AND STRATIFICATION

The Framingham Risk Score is a clinical tool of standard risk classification that is limited to assessing only short-term (10-year) risk of adverse cardiac events in patients without known CAD and where a high prevalence of subclinical ASCVD was found in women categorized as low risk. In 2011, based on clinical data on women at high risk and healthy women, the AHA established guidelines for cardiac risk assessment to target the prevention of ASCVD in women (Figure 2), with preeclampsia, and SLE gaining recognition in their contribution to female CV risk assessment. Expanding the ASCVD composite to include stroke and CHD, serious nonfatal outcome events, and mortality, the pooled cohort ASCVD risk equation was then derived in 2013 and incorporated traditional ASCVD risk factors. Although this risk stratification method was not developed specifically for women, as the 2011 guidelines were, it has been internally validated for several cohorts of women, including those from the WHI, ranging from 40 to 79 years, and provides a 10-year ASCVD risk estimate and lifetime risk estimate. Therefore, risk stratification of female patients should include both the 2013 ACC pooled cohort equation and assessment for risk factors unique to or predominant in
women, such as pregnancy complications and autoimmune disease, according to the 2011 guidelines.

7 | PREVENTIVE MEASURES

7.1 | Lifestyle modifications

The AHA/ACC recommends all adults consume a high intake of vegetables, fruits, and whole grains, as well as low-fat dairy products, poultry, fish, legumes, nontropical vegetable oils, and nuts. Three to 4 sessions per week of aerobic PA lasting an average of 40 min, at a moderate to vigorous intensity, for all adults is also recommended.29 Women may benefit more from PA than men, as the median ASCVD risk reduction associated with PA between most active women and least active women is 40%, whereas in men it is 30%.13 Therefore, the 2011 AHA guidelines for women recommend at least 150 min of moderate exercise per week or 75 min of vigorous exercise per week or a combination of both. Episodes of at least 10 min of aerobic activity spread throughout the week is also advised. For women who need to lose weight or sustain weight loss, a minimum of 60 to 90 min of at least moderate-intensity PA on most and preferably all days of the week is recommended.2 The 2013 AHA/ACC guidelines on lifestyle management may be used for all female patients, but some may find more benefit in the women-specific 2011 guidelines, especially those on weight loss. Women may also profit from attending female-only classes, as women have reported improved diet behavior and less depressive symptoms, compared to women attending mixed-sex classes.30

Solutions must be sought to reconcile the gap between current understanding of exercise’s CV benefits and implementation of exercise to reap those benefits. For instance, treating exercise frequency as a vital sign that is recorded routinely at doctors’ visits, viewing PA as a multidisease-targeting pharmaceutical equivalent that can be prescribed are ways in which PA can be incorporated into a complete care plan.

7.2 | Aspirin

The Women’s Health Study sought to evaluate the use of aspirin for primary prevention of ASCVD.31 Of the 40,000 healthy women, those who received 100 mg of aspirin every other day experienced a reduction in the risk of total strokes and ischemic strokes, with no difference in the risk of MI or death from CV events. Women age 65 years or older had significantly reduced risk of major cardiovascular events, ischemic stroke, and MI on aspirin. Therefore, the 2011 AHA guidelines for women recommend aspirin for women age 65 years or older have significantly reduced risk of major cardiovascular events, ischemic stroke, and MI on aspirin.

<p>| TABLE 2 | Summary of evidence for primary prevention with aspirin and statins in women |</p>
<table>
<thead>
<tr>
<th>Study</th>
<th>Study Type</th>
<th>Population</th>
<th>Intervention</th>
<th>Outcomes</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspirin</td>
<td>Women's Health Study 2005</td>
<td>Randomized controlled trial</td>
<td>40,000 healthy women</td>
<td>100 mg of aspirin every other day vs placebo</td>
<td>Stroke: RR: 0.83, 95% CI: 0.69-0.99, P = 0.04 Ischemic stroke: RR: 0.76, 95% CI: 0.63-0.93, P = 0.009 No significant difference in risk of MI or death from CV events Women age 65 years or older had significantly reduced risk of major cardiovascular events, ischemic stroke, and MI on aspirin.</td>
</tr>
<tr>
<td>Statins</td>
<td>JUPITER 2008</td>
<td>Randomized controlled trial</td>
<td>6801 healthy women (38.2% of study population)</td>
<td>20 mg of rosuvastatin daily vs placebo</td>
<td>MI: HR: 0.46; 95% CI: 0.3-0.7, P = 0.0002 Stroke: HR: 0.52; 95% CI: 0.34-0.79, P = 0.002 Revascularization or unstable angina: HR: 0.53; 95% CI: 0.4-0.7; P &lt; 0.00001 Combined endpoint of MI, stroke, or death from CV causes: HR: 0.53; 95% CI: 0.40-0.69, P &lt; 0.00001 Rosuvastatin significantly reduced the incidence of major cardiovascular events.</td>
</tr>
<tr>
<td>Walsh et al. 2004</td>
<td>Meta-analysis</td>
<td>6 trials of 11,435 women without CVD</td>
<td>Lipid-lowering medications (1 trial used colestipol; others used lovastatin, simvastatin, pravastatin, atorvastatin)</td>
<td>Total mortality: RR: 0.95, 95% CI: 0.62-1.46 CHD mortality: RR: 1.07, 95% CI: 0.47-2.40 Nonfatal MI: RR: 0.61, 95% CI: 0.22-1.68 Revascularization: RR: 0.87, 95% CI: 0.33-2.31 CHD events: RR: 0.87, 95% CI: 0.69-1.09</td>
<td>For primary prevention, lipid lowering did not affect total or CHD mortality or major cardiovascular events.</td>
</tr>
</tbody>
</table>

Abbreviations: CHD, coronary heart disease; CI, confidence interval; CV, cardiovascular; CVD, cardiovascular disease; HR, hazard ratio; MI, myocardial infarction; RR, relative risk.
7.3 | Statins

The Atherosclerosis Risk in Communities Study showed that elevated LDL and low HDL are independent risk factors for CHD in women, as are elevated triglyceride levels, which were not shown to have a similar association to CHD in men; these risk factors provided a larger relative risk of CHD in women than men. However, in primary prevention trials, lipid-lowering medications did not reduce total mortality, CHD mortality, MI, revascularization, or CHD events in women, despite lowering of cholesterol in both sexes (Table 2). The wider confidence intervals of these aforementioned endpoints in women are likely secondary to the overall lower incidence of CHD in women and their under-representation in these trials. With a large number of female participants (38.2%), the JUPITER trial concluded that women without overt dyslipidemia with increased hsCRP experienced a greater reduction in major adverse cardiac events than similarly affected men when placed on high-intensity rosuvastatin (Table 2).

A 2015 meta-analysis of 6 clinical trials, however, showed no significant difference in statin-related ASCVD benefits between the sexes. Given its lack of differing gender recommendations, the current 2013 ACC/AHA guidelines of treatment with statins should be considered for female patients, despite the existing, equivocal data on statins’ primary prevention benefits in women.

7.4 | Anticoagulation

Men have a greater risk of developing atrial fibrillation, but female gender is an independent risk for stroke in patients with atrial fibrillation. Some meta-analyses have demonstrated an increased stroke risk of 1.31 (95% CI: 1.18–1.46) for women with atrial fibrillation compared to men, leading to recommendation of the use of the CHA2DS2-VASc (Congestive heart failure, Hypertension, Age ≥ 75 years, Diabetes mellitus, Stroke or transient ischemic attack, Vascular disease, Age 65–74 years, Sex category), which incorporates a point for female sex. The reasons for this increased risk are more likely due to the comorbidities that increase the risk of thromboembolic events. With the advancement of direct oral anticoagulants, 4 studies have specifically investigated sex difference in efficacy of treatment, which illustrated no significant difference in stroke prevention with direct oral anticoagulants between females and males.

8 | GAPS, BARRIERS, AND FUTURE DIRECTIONS

After extensive efforts by the National Heart, Lung, and Blood Institute and the AHA’s Go Red for Women campaign, awareness of ASCVD in women increased from 30% in 1997 to 57% in 2006, but plateaued in 2009 with a lower rate among ethnic minorities. Some barriers to adherence women have cited are responsibilities as a caretaker and confusion in the media. Unfortunately, decreased awareness is also pervasive among physicians. Intermediate-risk women were more likely to be assessed as lower risk by primary care physicians, obstetricians/gynecologists, and cardiologists than men with identical risk profiles. Therefore, a focus on education of patients and physician training is necessary to decrease the persistently large global burden of ASCVD. Furthermore, additional women-specific clinical research is needed, as the majority of ASCVD trials have been in men. Updated guidelines on prevention of CV diseases in women are needed to assist with accurate clinical decisions and to optimize ASCVD prevention in half of the world’s population.

Conflicts of interest

The authors declare no potential conflicts of interest.

REFERENCES
